Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure

4 April 2022 (13:00 - 13:30)

Organised by:

About the speaker

Professor Avi Sabbag

Chaim Sheba Medical Center, Ramat Gan (Israel)

3 More presentations in this session

Presentation thumbnail

Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis

Mr M. Grymonprez (Gent, BE)

Abstract Slides

Presentation thumbnail

One-year results from the FLXibility post-approval study: final real-world clinical outcomes with a next-generation left atrial appendage closure device

Professor T. Betts (Oxford, GB)

Abstract Slides

Presentation thumbnail

Prevalence and outcomes of hypoattenuation defects and appendage patency on computed tomography after left atrial appendage closure

Professor H. Cochet (Bordeaux, FR)

Abstract Slides

Access the full session

Session thumbnail

Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

The Event

Event poster

EHRA 2022

4 April 2022 13:00 CET

You may be interested in

Congress Presentation

Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis

Congress Presentation

Single vs dual antiplatelet therapy after spontaneous coronary artery dissection

Congress Presentation

Oral anticoagulation monotherapy versus combination antithrombotic therapy in patients with AF and PCI with a drug-eluting stent implantation: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources